Update on Pparγ and nonalcoholic fatty liver disease

PPAR Research

Volumn , Issue , 2012, Pages

  Ables, Gene P ^a  

^a Orentreich Foundation for the Advancement of Science Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; N ACETYLFARNESYLCYSTEINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TELMISARTAN; UNCLASSIFIED DRUG;

BLADDER CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; FATTY ACID OXIDATION; FATTY LIVER; GENE DELETION; GENE TARGETING; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866149370     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/912351     Document Type: Review

References (65)

1. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., Grundy S. M., Hobbs H. H., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 6 1387 1395 2-s2.0-10644220306 10.1002/hep.20466 (Pubitemid 39657013)
2. Yki-Jarvinen H., Fat in the liver and insulin resistance. Annals of Medicine 2005 37 5 347 356 10.1080/07853890510037383 (Pubitemid 41379841)
3. Williams C. D., Stengel J., Asike M. I., Torres D. M., Shaw J., Contreras M., Landt C. L., Harrison S. A., Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011 140 1 124 131 2-s2.0-78650486196 10.1053/j.gastro.2010.09.038
4. Postic C., Girard J., The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes & Metabolism 2008 34 6 643 648 10.1016/S1262-3636(08)74599-3
5. Postic C., Girard J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation 2008 118 3 829 838 2-s2.0-40549135297 10.1172/JCI34275 (Pubitemid 351364588)
6. Brunt E. M., Tiniakos D. G., Histopathology of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2010 16 42 5286 5296 2-s2.0-78649433367 10.3748/wjg.v16.i42.5286
7. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005 115 5 1343 1351 2-s2.0-18244382304 10.1172/JCI200523621 (Pubitemid 40629054)
8. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K. S., Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002 35 4 898 904 2-s2.0-0036207720 10.1053/jhep.2002.32527 (Pubitemid 34258385)
9. Milic S., Stimac D., Nonalcoholic Fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Digestive Diseases 2012 30 2 158 162 10.1159/000336669
10. Koteish A., Diehl A. M., Animal models of steatosis. Seminars in Liver Disease 2001 21 1 89 104 2-s2.0-0035078599 (Pubitemid 32240489)
11. Nagarajan P., Kumar M. J. M., Venkatesan R., Majundar S. S., Juyal R. C., Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2012 18 11 1141 1153 10.3748/wjg.v18.i11.1141
12. Anstee Q. M., Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver International 2011 31 4 440 442 2-s2.0-79952471768 10.1111/j.1478-3231.2011.02463.x
13. Jou J., Choi S. S., Diehl A. M., Mechanisms of disease progression in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 370 379 2-s2.0-56649083495 10.1055/s-0028-1091981
14. Chitturi S., Abeygunasekera S., Farrell G. C., Holmes-Walker J., Hui J. M., Fung C., Karim R., Lin R., Samarasinghe D., Liddle C., Weltman M., George J., NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002 35 2 373 379 2-s2.0-18244364864 10.1053/jhep.2002.30692 (Pubitemid 34106377)
15. Guo L., Tabrizchi R., Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacology and Therapeutics 2006 111 1 145 173 10.1016/j.pharmthera.2005.10.009 (Pubitemid 43765533)
16. Saraf N., Sharma P. K., Mondal S. C., Garg V. K., Singh A. K., Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. Journal of Pharmacy and Pharmacology 2012 64 2 161 171 10.1111/j.2042-7158.2011. 01366.x
17. Whitehead J. P., Diabetes: new conductors for the peroxisome proliferator-activated receptor gamma (PPAR γ) orchestra. International Journal of Biochemistry and Cell Biology 2011 43 8 1071 1074 10.1016/j.biocel.2011.04.017
18. Choi J. H., Banks A. S., Estall J. L., Kajimura S., Boström P., Laznik D., Ruas J. L., Chalmers M. J., Kamenecka T. M., Blüher M., Griffin P. R., Spiegelman B. M., Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR γ 3 by Cdk5. Nature 2010 466 7305 451 456 2-s2.0-77954941113 10.1038/nature09291
19. Cornelius P., MacDougald O. A., Lane M. D., Regulation of adipocyte development. Annual Review of Nutrition 1994 14 99 129 (Pubitemid 24261832)
20. Chawla A., Schwarz E. J., Dimaculangan D. D., Lazar M. A., Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994 135 2 798 800 2-s2.0-0028015713 10.1210/en.135.2.798 (Pubitemid 24241266)
21. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes and Development 1994 8 10 1224 1234 2-s2.0-0028180070
22. Kallwitz E. R., McLachlan A., Cotler S. J., Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2008 14 1 22 28 2-s2.0-39849099238 10.3748/wjg.14.22 (Pubitemid 351314322)
23. Wu Z., Xie Y., Morrison R. F., Bucher N. L. R., Farmer S. R., PPAR γ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBP α during the conversion of 3T3 fibroblasts into adipocytes. Journal of Clinical Investigation 1998 101 1 22 32 (Pubitemid 28058899)
24. Kim J. B., Spiegelman B. M., ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes and Development 1996 10 9 1096 1107 2-s2.0-0030007427 (Pubitemid 26152851)
25. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A. M., Saladin R., Najib J., Laville M., Fruchart J. C., Deeb S., Vidal-Puig A., Flier J., Briggs M. R., Staels B., Vidal H., Auwerx J., The organization, promoter analysis, and expression of the human PPAR γ gene. Journal of Biological Chemistry 1997 272 30 18779 18789 2-s2.0-0030835678 10.1074/jbc.272.30.18779 (Pubitemid 27318225)
26. Tontonoz P., Hu E., Spiegelman B. M., Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 1994 79 7 1147 1156 2-s2.0-0028641559
27. Camirand A., Marie V., Rabelo R., Silva J. E., Thiazolidinediones stimulate uncoupling protein-2 expression in cell lines representing white and brown adipose tissues and skeletal muscle. Endocrinology 1998 139 1 428 431 10.1210/en.139.1.428 (Pubitemid 28166339)
28. Browning J. D., Horton J. D., Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation 2004 114 2 147 152 10.1172/JCI200422422 (Pubitemid 39071617)
29. Vidal-Puig A., Jimenez-Liñan M., Lowell B. B., Hamann A., Hu E., Spiegelman B., Flier J. S., Moller D. E., Regulation of PPAR γ gene expression by nutrition and obesity in rodents. Journal of Clinical Investigation 1996 97 11 2553 2561 2-s2.0-0030000088 (Pubitemid 26187343)
30. Moran-Salvador E., Lopez-Parra M., Garcia-Alonso V., Titos E., Martinez-Clemente M., Gonzalez-Periz A., Lopez-Vicario C., Barak Y., Arroyo V., Claria J., Role for PPAR γ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB Journal 2011 25 8 2538 2550 10.1096/fj.10-173716
31. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., Ide T., Kubota N., Terauchi Y., Tobe K., Miki H., Tsuchida A., Akanuma Y., Nagai R., Kimura S., Kadowaki T., The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPAR γ) deficiency and PPAR γ agonist improve insulin resistance. Journal of Biological Chemistry 2001 276 44 41245 41254 2-s2.0-0035798713 10.1074/jbc.M103241200
32. Yoneda M., Hotta K., Nozaki Y., Endo H., Uchiyama T., Mawatari H., Iida H., Kato S., Hosono K., Fujita K., Yoneda K., Takahashi H., Kirikoshi H., Kobayashi N., Inamori M., Abe Y., Kubota K., Saito S., Maeyama S., Wada K., Nakajima A., Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology 2008 8 27 2-s2.0-47749134925 10.1186/1471-230X-8-27 (Pubitemid 352025048)
33. Hui Y., Yu-yuan L., Yu-qiang N., Wei-hong S., Yan-lei D., Xiao-bo L., Yong-jian Z., Effect of peroxisome proliferator-activated receptors- γ and co-activator-1 α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver International 2008 28 3 385 392 2-s2.0-39549113664 10.1111/j.1478-3231.2007. 01623.x (Pubitemid 351279587)
34. Dongiovanni P., Rametta R., Fracanzani A. L., Benedan L., Borroni V., Maggioni P., Maggioni M., Fargion S., Valenti L., Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2010 10 102 2-s2.0-77956461321 10.1186/1471-230X-10-102
35. Gawrieh S., Marion M.C., Komorowski R., Wallace J., Charlton M., Kissebah A., Langefeld C.D., Olivier M., Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Digestive Diseases and Sciences 2011 57 4 952 957 10.1007/s10620-011-1994-2
36. Gupta A. C., Chaudhory A. K., Sukriti, Pande C., Sakhuja P., Singh Y., Basir S. F., Sarin S. K., Peroxisome proliferators-activated receptor γ 2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatology International 2011 5 1 575 580 2-s2.0-79952631265 10.1007/s12072-010-9225-z
37. Rey J. W., Noetel A., Hardt A., Canbay A., Alakus H., zur Hausen A., Dienes H. P., Drebber U., Odenthal M., Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor γ 2 in patients with fatty liver diseases. World Journal of Gastroenterology 2010 16 46 5830 5837 2-s2.0-78650592847 10.3748/wjg.v16.i46.5830
38. Yang Z., Wen J., Li Q., Tao X., Ye Z., He M., Zhang W., Huang Y., Chen L., Ling C., Qu S., Hu R., PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Molecular and Cellular Endocrinology 2012 348 1 255 259 10.1016/j.mce.2011.09.001
39. Inoue M., Ohtake T., Motomura W., Takahashi N., Hosoki Y., Miyoshi S., Suzuki Y., Saito H., Kohgo Y., Okumura T., Increased expression of PPAR γ in high fat diet-induced liver steatosis in mice. Biochemical and Biophysical Research Communications 2005 336 1 215 222 2-s2.0-24344468717 10.1016/j.bbrc.2005.08.070 (Pubitemid 41253423)
40. Yu S., Matsusue K., Kashireddy P., Cao W. Q., Yeldandi V., Yeldandi A. V., Rao M. S., Gonzalez F. J., Reddy J. K., Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ 1 (PPAR γ 1) overexpression. Journal of Biological Chemistry 2003 278 1 498 505 2-s2.0-0346003777 10.1074/jbc.M210062200 (Pubitemid 36043602)
41. Uno K., Katagiri H., Yamada T., Ishigaki Y., Ogihara T., Imai J., Hasegawa Y., Gao J., Kaneko K., Iwasaki H., Ishihara H., Sasano H., Inukai K., Mizuguchi H., Asano T., Shiota M., Nakazato M., Oka Y., Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006 312 5780 1656 1659 2-s2.0-33745151403 10.1126/science.1126010 (Pubitemid 43902665)
42. Matsusue K., Kusakabe T., Noguchi T., Takiguchi S., Suzuki T., Yamano S., Gonzalez F. J., Hepatic steatosis in leptin-deficient mice is promoted by the PPAR γ target gene Fsp27. Cell Metabolism 2008 7 4 302 311 2-s2.0-41449098953 10.1016/j.cmet.2008.03.003 (Pubitemid 351455219)
43. Gavrilova O., Haluzik M., Matsusue K., Cutson J. J., Johnson L., Dietz K. R., Nicol C. J., Vinson C., Gonzalez F. J., Reitman M. L., Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. Journal of Biological Chemistry 2003 278 36 34268 34276 2-s2.0-0141446024 10.1074/jbc.M300043200 (Pubitemid 37553270)
44. Zhang Y. L., Hernandez-Ono A., Siri P., Weisberg S., Conlon D., Graham M. J., Crooke R. M., Huang L. S., Ginsberg H. N., Aberrant hepatic expression of PPAR γ 2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. Journal of Biological Chemistry 2006 281 49 37603 37615 2-s2.0-33845984572 10.1074/jbc.M604709200 (Pubitemid 46042063)
45. Nan Y.-M., Fu N., Wu W.-J., Liang B.-L., Wang R.-Q., Zhao S.-X., Zhao J.-M., Yu J., Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scandinavian Journal of Gastroenterology 2009 44 3 358 365 10.1080/00365520802530861
46. Nan Y. M., Han F., Kong L. B., Zhao S. X., Wang R. Q., Wu W. J., Yu J., Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scandinavian Journal of Gastroenterology 2011 46 3 358 369 2-s2.0-79751491258 10.3109/00365521.2010.525717
47. Sun X., Tang Y., Tan X., Li Q., Zhong W., Sun X., Jia W., McClain C. J., Zhou Z., Activation of peroxisome proliferator-activated receptor- γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012 302 5 G548 G557 10.1152/ajpgi.00342.2011
48. Yang S. J., Choi J. M., Chae S. W., Kim W. J., Park S. E., Rhee E. J., Lee W. Y., Oh K. W., Park S. W., Kim S. W., Park C. Y., Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases Sirt6 expression and ameliorates hepatic steatosis in rats. PLoS ONE 2011 6 2 2-s2.0-79952032653 10.1371/journal.pone.0017057 e17057
49. Berthiaume M., Laplante M., Festuccia W. T., Berger J. P., Thieringer R., Deshaies Y., Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. International Journal of Obesity 2009 33 5 601 604 2-s2.0-67349178689 10.1038/ijo.2009.33
50. Elshorbagy A. K., Valdivia-Garcia M., Mattocks D. A. L., Plummer J. D., Smith A. D., Drevon C. A., Refsum H., Perrone C. E., Cysteine supplementation reverses methionine restriction effects on rat adiposity: significance of stearoyl-coenzyme a desaturase. Journal of Lipid Research 2011 52 1 104 112 2-s2.0-78650900717 10.1194/jlr.M010215
51. Malloy V. L., Krajcik R. A., Bailey S. J., Hristopoulos G., Plummer J. D., Orentreich N., Methionine restriction decreases visceral fat mass and preserves insulin action in aging male Fischer 344 rats independent of energy restriction. Aging Cell 2006 5 4 305 314 2-s2.0-33746302753 10.1111/j.1474-9726. 2006.00220.x (Pubitemid 44103246)
52. Plaisance E. P., Greenway F. L., Boudreau A., Hill K. L., Johnson W. D., Krajcik R. A., Perrone C. E., Orentreich N., Cefalu W. T., Gettys T. W., Dietary methionine restriction increases fat oxidation in obese adults with metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 5 E836 E840 2-s2.0-79955659470 10.1210/jc.2010-2493
53. Broulik P. D., Sefc L., Haluzik M., Effect of PPAR-gamma agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice. Folia Biologica 2011 57 4 133 138
54. Bedoucha M., Atzpodien E., Boelsterli U. A., Diabetic KKAy mice exhibit increased hepatic PPAR γ 1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. Journal of Hepatology 2001 35 1 17 23 2-s2.0-0034743328 10.1016/S0168-8278(01)00066-6 (Pubitemid 32646220)
55. Colmers I. N., Bowker S. L., Majumdar S. R., Johnson J. A., Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Canadian Medical Association Journal. In press 10.1503/cmaj.112102
56. Rangwala S. M., Lazar M. A., The dawn of the SPPARMs? Sciences STKE 2002 2002 121 PE9 2-s2.0-0037177058
57. Wang M., Tafuri S., Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. Journal of Cellular Biochemistry 2003 89 1 38 47 (Pubitemid 36459096)
58. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M. F., Plunket K. D., Leesnitzer L. M., Blanchard S. G., Desreumaux P., Moras D., Renaud J. P., Auwerx J., A unique PPAR γ ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular Cell 2001 8 4 737 747 2-s2.0-2642557181 10.1016/S1097-2765(01)00353-7 (Pubitemid 33030208)
59. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., Kintscher U., Molecular characterization of new selective peroxisome proliferator- activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 2005 54 12 3442 3452 2-s2.0-33644672013 10.2337/diabetes.54.12.3442 (Pubitemid 43334334)
60. Berger J. P., Petro A. E., Macnaul K. L., Kelly L. J., Zhang B. B., Richards K., Elbrecht A., Johnson B. A., Zhou G., Doebber T. W., Biswas C., Parikh M., Sharma N., Tanen M. R., Thompson G. M., Ventre J., Adams A. D., Mosley R., Surwit R. S., Moller D. E., Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Molecular Endocrinology 2003 17 4 662 676 2-s2.0-12444273748 10.1210/me.2002-0217 (Pubitemid 36403578)
61. Bhalla K., Hwang B. J., Choi J. H., Dewi R., Ou L., Mclenithan J., Twaddel W., Pozharski E., Stock J., Girnun G. D., N-acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo. Journal of Biological Chemistry 2011 286 48 41626 41635 10.1074/jbc.M111.257915
62. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., Wahli W., A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Molecular Endocrinology 2002 16 11 2628 2644 2-s2.0-0036843143 10.1210/me.2002-0036 (Pubitemid 35266080)
63. Higgins L. S., Mantzoros C. S., The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer. PPAR Research 2008 2008 936906
64. Lee D. H., Huang H., Choi K., Mantzoros C., Kim Y. B., Selective PPARgamma modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. American Journal of Physiology- Endocrinology and Metabolism 2012 302 5 552 560 10.1152/ajpendo.00569.2011
65. Dunn F. L., Higgins L. S., Fredrickson J., Depaoli A. M., Selective modulation of PPAR γ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Journal of Diabetes and its Complications 2011 25 3 151 158 2-s2.0-79955064893 10.1016/j.jdiacomp.2010.06.006